Cargando…
Activin Receptor Ligand Blocking and Cancer Have Distinct Effects on Protein and Redox Homeostasis in Skeletal Muscle and Liver
Muscle wasting in cancer cachexia can be alleviated by blocking activin receptor type 2 (ACVR2) ligands through changes in protein synthesis/degradation. These changes in cellular and protein metabolism may alter protein homeostasis. First, we elucidated the acute (1–2 days) and 2-week effects of bl...
Autores principales: | Hentilä, Jaakko, Nissinen, Tuuli A., Korkmaz, Ayhan, Lensu, Sanna, Silvennoinen, Mika, Pasternack, Arja, Ritvos, Olli, Atalay, Mustafa, Hulmi, Juha J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345696/ https://www.ncbi.nlm.nih.gov/pubmed/30713500 http://dx.doi.org/10.3389/fphys.2018.01917 |
Ejemplares similares
-
Blocking Activin Receptor Ligands Is Not Sufficient to Rescue Cancer-Associated Gut Microbiota—A Role for Gut Microbial Flagellin in Colorectal Cancer and Cachexia?
por: Pekkala, Satu, et al.
Publicado: (2019) -
Prevention of chemotherapy‐induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle
por: Hulmi, Juha J., et al.
Publicado: (2017) -
Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses
por: Nissinen, Tuuli A., et al.
Publicado: (2018) -
Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy
por: Puolakkainen, Tero, et al.
Publicado: (2017) -
Upregulation of activin-B and follistatin in pulmonary fibrosis – a translational study using human biopsies and a specific inhibitor in mouse fibrosis models
por: Myllärniemi, Marjukka, et al.
Publicado: (2014)